Ikonomidis I et al. |
Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. |
2005 |
Am. Heart J. |
pmid:15894964
|
Coppola A et al. |
Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. |
2005 |
Br. J. Haematol. |
pmid:16173969
|
Haubelt H et al. |
Can platelet function tests predict the clinical efficacy of aspirin? |
2005 |
Semin. Thromb. Hemost. |
pmid:16149017
|
Saloheimo P et al. |
Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. |
2005 |
Thromb. Res. |
pmid:15733969
|
De Candia E et al. |
Abnormal pH-sensing of platelet Na+/H+ exchanger in patients with cardiac syndrome X. |
2005 |
Int. J. Cardiol. |
pmid:15837078
|
Sciulli MG et al. |
Platelet activation in patients with colorectal cancer. |
2005 |
Prostaglandins Leukot. Essent. Fatty Acids |
pmid:15626589
|
Gonzalez-Conejero R et al. |
Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? |
2005 |
Stroke |
pmid:15604423
|
Böhm E et al. |
11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. |
2004 |
J. Biol. Chem. |
pmid:14668348
|
Suzuki N et al. |
Quantitative liquid chromatography-tandem mass spectrometric analysis of 11-dehydro TXB2 in urine. |
2004 |
Prostaglandins Other Lipid Mediat. |
pmid:15165035
|
Perneby C et al. |
Prothrombotic responses to exercise are little influenced by clopidogrel treatment. |
2004 |
Thromb. Res. |
pmid:15381386
|
Hennekens CH et al. |
Terms and conditions: semantic complexity and aspirin resistance. |
2004 |
Circulation |
pmid:15381661
|
Ferroni P et al. |
Platelet activation in type 2 diabetes mellitus. |
2004 |
J. Thromb. Haemost. |
pmid:15304032
|
Bruno A et al. |
Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. |
2004 |
Stroke |
pmid:14963281
|
Minuz P et al. |
Determinants of platelet activation in human essential hypertension. |
2004 |
Hypertension |
pmid:14656953
|
Vainio M et al. |
Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. |
2004 |
Acta Obstet Gynecol Scand |
pmid:15548142
|
Capone ML et al. |
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. |
2004 |
Circulation |
pmid:15037526
|
Ikonomidis I et al. |
Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. |
2004 |
Heart |
pmid:15020512
|
Dippel DW et al. |
What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? |
2004 |
Cerebrovasc. Dis. |
pmid:15026612
|
De Cristofaro R et al. |
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. |
2003 |
J. Thromb. Haemost. |
pmid:12871497
|
Davì G et al. |
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. |
2003 |
Circulation |
pmid:12810609
|